glp-1 agonists and sglt2 inhibitors Combining Receptor in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique | Diabetes Therapy SGLT2 inhibitors or GLP-1 receptor
Description
To develop oral peptide formulations, Novo Nordisk turned to salcaprozate sodium, an excipient also known as sodium N -[8-(2-hydroxybenzoyl)amino]caprylate or SNAC, that was developed by the drug delivery company Emisphere
Nat Rev
Creatine helps preserve muscle mass during rapid weight loss
A., Yang, Z., Zeng, C
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks
doi: 10.1001/jama.281.8.727
